Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers
Ipsen And BAKX Will Develop Latter’s BCL-2 Inhibitor
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
